PDS BIOTECHNOLOGY CORPORATION - COMMON STOCK

PDS Biotech to Participate in Cantor’s Future of Oncology Virtual Symposium 

29 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2022 Financial Results

28 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter 2022 Financial Results

16 Mar 2023 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech to Participate at 33rd Annual Oppenheimer Healthcare Conference

07 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces the Publication of PDS0301 Study Linking Induced Changes in Immune Responses with Clinical Outcomes in International Immunopharmacology Journal

01 Mar 2023 08:00:02 By Nasdaq GlobeNewswire

PDS Biotech Completes Successful Meeting with FDA for Triple Combination of PDS0101, PDS0301 and a Commercial Immune Checkpoint Inhibitor

27 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune™

16 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces Publication of Preclinical Infectimune™ Based Vaccine Studies Demonstrating Effective Protection Against Viral Infection in Peer-Reviewed Journal, Viruses

08 Feb 2023 16:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Abstract Accepted for Presentation at ESMO Targeted Anticancer Therapies Congress

06 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces Participation in the Channelchek Takeaway Series

26 Jan 2023 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech to Participate at the B. Riley Securities 3rd Annual Oncology Conference

13 Jan 2023 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany

03 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech Reports Median Overall Survival (OS) of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options and with Reported Historical Survival of 3-4 months

28 Dec 2022 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer

15 Dec 2022 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Executives to Present an Overview of Oncology and Infectious Disease Programs at the World Vaccine & Immunotherapy Congress

21 Nov 2022 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Reports Third Quarter 2022 Financial Results and Provides Business Update

14 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

PDS Biotech Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Clinical Trial

14 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces Presentation of Preliminary PDS0101 Efficacy, Safety, and Immunology Data at Society for Immunotherapy of Cancer (SITC 2022)

07 Nov 2022 08:00:03 By Nasdaq GlobeNewswire

PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2022 Financial Results

31 Oct 2022 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Provides Highlights from Head and Neck Cancer KOL Roundtable

27 Oct 2022 08:00:01 By Nasdaq GlobeNewswire